The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for ...

Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3 ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

Vanguard Group Inc. raised its stake in Biohaven Ltd. (NYSE:BHVN – Free Report) by 8.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC.The institutional ...

Biohaven (BHVN) announced that it will present 13 abstracts at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California.

Chinese drug makers landed 33 licensing deals with overseas pharmaceutical firms, with transactions totalling US$36.2 billion ...

Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, ...

Swiss National Bank raised its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 12.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 154,800 ...

Xenon Pharmaceuticals Inc.'s XEN1101 shows promise in epilepsy with strong phase 2b results and solid financials. Click here ...

The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing ...

SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN ...